MedTrace Logo

Uterovaginal Plexus Block With Articaine for Intrauterine Device Placement Patients Who Are Indicated for the Use of Copper IUD as a Contraceptive Method Will be Invited to Participate in This Research.

NCT05252117 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2022-02-23

No results posted yet for this study

Summary

The use of intrauterine device (IUD) in Brazil is still not very significant and one of the reasons is the fear of feeling pain during its insertion procedure. Articaine is an amide-linked local anesthetic, its plasma half-life is shorter than that of most other amide-type anesthetics, which makes it theoretically favorable in relation to systemic toxicity.

Conditions

  • Contraception
  • IUD
  • Anesthesia, Local

Interventions

DRUG

Articaine Hydrochloride 40 MG/ML

Analysis of uterovaginal plexus block with articain for intrauterine device placement

DRUG

Mepivacaine

Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement

Sponsors & Collaborators

  • Universidade do Vale do Sapucai

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-04-30
Completion
2022-12-10

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05252117 on ClinicalTrials.gov